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Abstract
Background: Automated peritoneal dialysis (APD) is one of the fastest growing dialysis modalities. It is unknown
whether sleep and mood are disturbed while performing repeated overnight exchanges.
Objectives: In this report, we aim to describe and compare the prevalence of sleep-disordered breathing (SDB), periodic
limb movements (PLMS), poor sleep quality (SQ), and depression among APD patients compared with stages 3b–5
(estimated glomerular filtration rate ≤44 ml/min/1.73 m2) chronic kidney disease (CKD) and hemodialysis (HD) patients.
Design: This is a cross-sectional, descriptive study.
Setting: Study participants were recruited from outpatient nephrology clinics, local dialysis centers, and the Thomas E.
Starzl Transplant Institute in Western Pennsylvania between April 2004 and July 2009.
Patients: There were 186 participants in this study including 22 APD patients, 89 CKD patients, and 75 HD patients.
Measurements: In-home polysomnography was performed and two questionnaires were completed, the Pittsburgh
Sleep Quality Index (PSQI) and the Patient Health Questionnaire-9 (PHQ-9).
Methods: SDB and PLMS were quantified by in-home unattended polysomnography; poor SQ was defined by a score
>5 on the PSQI, and the presence of moderate to severe depression was defined by a score >5 on the PHQ-9.
Results: The APD patients had a median age of 37.5 years, were predominantly female (72.7 %), and had a median
body mass index (BMI) of 23.8 kg/m2. In univariate analyses, APD patients had significantly lower apnea-hypopnea
index compared to HD patients by 12.2 points (likelihood ratio test p = 0.008) and revealed the least percent of TST
with nocturnal hypoxemia compared to CKD patients by 2.7 points, respectively (likelihood ratio test p = 0.01). The
APD group had also significantly greater stages 3 to 4 sleep compared to the CKD patients by 8.6 points (likelihood
ratio test p = 0.009). In multivariate analyses and after adjustment for age, gender, race, and BMI, both APD and HD
patients had higher average PSQI scores than CKD patients by 2.54 and 2.22 points, respectively (likelihood ratio test
p = 0.005). No other comparisons of sleep parameters among groups reached statistical significance.
Limitations: The limitations of this study are the small sample size of the APD population and the demographic and
clinical differences among the three study groups.
Conclusions: Despite differences in univariate analyses, after multivariate adjustment, APD patients had similar sleep
parameters and sleep architecture and as poor SQ and symptoms of depression as HD patients. Future studies with
larger APD cohorts are needed.
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ABRÉGÉ
Mise en contexte: La dialyse péritonéale automatisée (DPA) est l’une des méthodes de traitement pour
l’insuffisance rénale terminale connaissant la plus forte croissance. Toutefois, l’influence de la pratique répétée de
cette procédure sur la qualité du sommeil et sur l’humeur du patient demeure peu documentée.
Objectifs de l’étude: L’étude visait à caractériser et à définir la prévalence de troubles respiratoires du sommeil, de
mouvements involontaires des membres, d’effets sur la qualité du sommeil et de symptômes dépressifs chez les
patients sous DPA en comparaison avec la prévalence de ces mêmes paramètres chez les patients souffrant
d’insuffisance rénale chronique (eDFG à ≤44 ml/min/1.73 m2) et chez les patients sous hémodialyse.
Cadre et type d’étude: Il s’agit d’une étude transversale descriptive qui s’est tenue dans l’ouest de la Pennsylvanie
(États-Unis) entre avril 2004 et juillet 2009. Le recrutement des participants s’est effectué au sein des patients en
consultation externe des cliniques de néphrologie, dans les centres de dialyses régionaux et au Thomas E. Starzl
Transplant Institute.
Participants: Un total de 186 patients a pris part à cette étude, parmi lesquels on comptait 22 patients sous
traitement par DPA, 89 patients en situation d’insuffisance rénale chronique et 75 patients sous hémodialyse.
Mesures: La cueillette des données incluait des mesures de polysomnographie effectuées à domicile par les
patients ainsi que les réponses fournies à deux questionnaires : le Pittsburgh Sleep Quality Index (PSQI) et le Patient
Health Questionnaire-9 (PHQ-9).
Résultats: La cohorte de patients sous DPA se constituait en majorité de femmes (72,3 %) de 37,5 ans d’âge
médian et dont l’indice de masse corporelle (IMC) se situait en moyenne à 23,8 kg/m2. Les analyses univariées ont
démontré un index apnées-hypopnées inférieur de 12,2 points (p = 0,0008) et un plus faible pourcentage de
troubles du sommeil avec hypoxémie nocturne par 2,7 points (p = 0,01) chez les patients sous DPA en comparaison
avec les patients sous hémodialyse. Les analyses multivariées, après correction en fonction de l’âge, du sexe, de
l’origine ethnique et de l’IMC des participants, ont quant à elles démontré que les patients sous DPA et sous
hémodialyse ont obtenu des résultats plus élevés au questionnaire PSQI que les patients souffrant d’insuffisance
rénale chronique, avec des moyennes supérieures de 2,54 et 2,22 points respectivement (p = 0,005). La comparaison
entre les différents groupes en ce qui concerne les autres paramètres mesurés n’a pas atteint le degré de
signification statistique.
Limites de l’étude: Les données recueillies au cours de cette étude concernent un faible échantillon de patients
sous DPA. De plus, en raison des grandes différences notées dans les données cliniques et démographiques des
trois groupes de patients qui la constituaient, la cohorte étudiée manquait d’uniformité.
Conclusions: En dépit des différences notées dans les analyses univariées et de l’obligation d’effectuer des
corrections dans les analyses multivariées, les résultats montrent que les patients sous DPA ne présentent pas de
différences significatives pour les paramètres de sommeil mesurés. Les patients sous DPA maintiennent des
paramètres et une architecture de sommeil semblables à ceux mesurés chez les patients sous traitement par
hémodialyse : la qualité du sommeil demeure faible, mais ils ne présentent pas plus de symptômes de dépression.
Des études de plus grande envergure sont requises afin de mieux définir l’influence de la DPA sur la qualité du
sommeil et sur l’humeur des patients qui la pratiquent.
Sleep-disordered breathing and periodic limb
movements are two of the most frequent sleep
disorders among patients undergoing peritoneal
dialysis, while depression is a major factor
contributing to their poor sleep quality. Sleep and
mood assessment among APD patients has been
overlooked despite the substantial health burden
associated with sleep disturbances and depression.
This report adds to the pre-existing knowledge by
examining by objective and subjective means sleep
and mood among automated peritoneal dialysis
patients and by comparing them to stages 3b–5
chronic kidney disease and hemodialysis patients.
Background
Symptoms of poor sleep are commonly reported among
patients with chronic kidney disease (CKD) and end-stage
renal disease (ESRD) dependent on dialysis. However,
most reports focus on patients undergoing hemodialysis
(HD). This overlooks patients performing automated peri-
toneal dialysis (APD), which is the fastest growing dialysis
modality, and unique in that dialysis is performed at home
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largely during sleep. In patients undergoing peritoneal
dialysis (PD), sleep-disordered breathing (SDB), rest-
less legs syndrome, and periodic limb movements
(PLMS) in sleep are thought to be the most common
sleep disorders [1]. Negative emotional states (e.g.,
depression), somatic symptoms, and treatment-related
issues (e.g., cycler alarms) are some of the factors
contributing to poor sleep quality (SQ) in this vulner-
able patient population [2, 3].
While treatment-related aspects of APD may nega-
tively influence SQ, SDB is the most frequently re-
ported sleep disorder in ESRD (50–80 % in most
studies) [2, 4–7] and has been related mostly to
chronic fluid retention [8], uremia [8], and abdominal
dialysate bulk load during the night exchanges [6].
APD patients seem to have less severe SDB compared
to continuous ambulatory PD patients, perhaps due
to more effective ultrafiltration and solute clearance
[4]. PLMS are also highly prevalent (40–70 %) in
patients on maintenance dialysis (PD or HD) [9–12]
and have been associated with SDB and mortality in
these patients [13, 14]. Although depression is com-
mon among patients on chronic dialysis [15, 16] and
may be a significant contributor to their poor SQ,
previous studies comparing dialysis modalities as well
as examining the emotional well-being and the pres-
ence of depression among PD patients have reported
contradictory findings.
Sleep assessment among APD patients has been over-
looked despite the substantial health burden associated
with sleep disturbances. Sleep disorders can lead to
excessive daytime sleepiness [17] and unintentional nap-
ping during the day [18], reduced sleep quantity and
quality [2], psychological distress [17], cognitive dysfunc-
tion [19], reduced quality of life [20], and chronic
inflammation [21, 22] and have been associated with
increased cardiovascular and all-cause mortality [23] in
PD patients. These disorders have also been linked to
greater use of health services, increased use of hyp-
notics, and reduced functional capabilities [24]. Poor
self-reported SQ occurs in 47–80 % of PD patients
[25–27] and correlates significantly with psychosocial
problems, marital status, educational background, and
patients’ perceptions of quality of life [28]. Few prior
studies have examined sleep disorders in patients on
PD and compared to HD and advanced CKD patients
[2, 29]. These studies have largely focused on symp-
tomatic continuous ambulatory PD patients and over-
looked important outcomes such as sleep efficiency
and sleep arousals.
In this report, we aimed to characterize SDB, PLMS,
SQ, and depression among cycler-assisted APD patients.
We also compared those sleep parameters against stages
3b–5 CKD and to HD patients.
Methods
Study setting, samples, and design
Patients
For this report, 22 APD, 89 non-dialysis-dependent CKD
patients, and 75 HD patients were enrolled from
outpatient nephrology clinics, local dialysis centers, and
the Thomas E. Starzl Transplant Institute in Western
Pennsylvania between April 2004 and July 2009. Patients
were eligible to participate if they were >18 years and
had advanced CKD (Modification of Diet in Renal
Disease-derived estimated glomerular filtration rate, esti-
mated glomerular filtration rate (eGFR) ≤44 ml/min/
1.73 m2). Patients were excluded for use of continuous
positive airway pressure and for active medical or psy-
chiatric disease (e.g., unstable angina, alcohol abuse).
Potential study participants were approached and in-
formed about the sleep study by clinical staff who was
directly involved in their care or by study coordinators
themselves while visiting their clinic. No “cold-calling”
occurred for study recruitment. If interested in research
study participation, the clinician would instruct the
participant to either contact the research team directly
for additional information or the participant would
directly provide a signed IRB-approved written consent
form and a signed written HIPPA authorization form to
our research staff.
The 89 CKD and 75 HD remaining patients who
participated in the sleep studies are included in this
report. Of note, much of the data from these two
comparison groups have been published in a comparison
with controls from the Sleep Strategies Concentrating
on Risk Evaluation (SCORE) study [30]. Patient prefer-
ence determined the night of polysomnography (PSG)
conduct relative to their HD day. Of the 67 HD patients
with available data, 31 (41.3 %) and 36 (48 %) patients
were studied the evening after and before their session,
respectively. Of the 57 HD patients with available shift
data, 40 were in the morning (5:30 to 10:00 a.m.), 16 in
the afternoon (10:00 a.m. to 3:30 p.m.), and 1 in the
evening shift (3:30 to 5:30 p.m.).
The study was approved by the University of Pittsburgh
IRB, and all participants provided written informed
consent.
Data collection
Baseline data collection for all participants included
a brief standardized health interview, questionnaire
administration, assessment of antihypertensives (total
number used at the time of the study), systolic and
diastolic blood pressure before the PSG assessment,
weight, height, neck and waist circumference, and
unattended home PSG.
In addition, two measurements of systolic and diastolic
blood pressure were performed within at least 2–3 min
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before each PSG study using an automated cuff. If
there was an over 4-mmHg discrepancy between the
two cuff readings, a third measurement was per-
formed. Serum creatinine, eGFR, and serum glucose
within 6 months from the date of the study were also
recorded for all groups.
Sleep assessment—polysomnography
Unattended in-home PSG was performed using an
ambulatory Compumedics Siesta monitor (Charlotte,
North Carolina) at habitual sleep times. Patients’ prefer-
ence determined the night of PSG conduction. APD
patients also performed their therapy on the same night.
The sleep study montage included bilateral central and
occipital electroencephalogram (EEG) channels, bilateral
electrooculograms (EOGs), bipolar submentalis electro-
myograms (EMGs), and one channel of electrocardio-
gram (ECG) recording. Bipolar ECG and position
sensors were used to monitor heart rate and body
position, respectively. On the night of PSG, participants
were also monitored for respiratory parameters, nasal
pressure, and for abdominal and thoracic effort using
finger pulse oximetry (Nonin, Minneapolis, MN), nasal-
oral thermocouple, and inductance plethysmography,
respectively. High-frequency filter settings were 100 Hz
for EEG and EOG and 70 Hz for EMG. Low-frequency
filter settings were 0.3 Hz for EEG and 10 Hz for
EMG [31].
Scoring of polysomnograms—sleep parameter definitions
Centrally trained PSG technologists scored sleep records
for all study groups according to the Rechtschaffen and
Kales guidelines using standard sleep stage scoring
criteria for each 20-s epoch [32]. All scorers were
blinded to the renal function of the patients. Standard
definitions were used to identify apneas and hypopneas;
oximetry readings were used to quantify average and
minimum oxyhemoglobin saturation levels. Apnea was
defined as a complete or an almost complete (≤25 % of
baseline) airflow cessation, measured by the amplitude
of the ≥10-s nasal pressure signal. Hypopnea was defined
as a ≥10-s abnormal respiratory event with ≥30 % airflow
reduction (compared to baseline) and was associated
with ≥4 % oxyhemoglobin desaturation. Limb move-
ments were defined as periodic if they were separated by
at least 5 s and not more than 90 s.
PSG outcome variables in the analysis included total
sleep time (sleep time excluding periods of wakefulness
during the night); sleep efficiency (percentage of total
sleep time as a proportion of the total recording dur-
ation); parameters of sleep architecture (percentage of
total sleep time spent in non-rapid eye movement
(NREM) stage 1, stage 2, and stages 3–4 and rapid eye
movement (REM) sleep); apnea-hypopnea index (AHI,
number of apneas and hypopneas/hour of sleep); micro-
arousal index (number of microarousals/hour of sleep);
nocturnal hypoxemia (percent of total sleep time with
oxyhemoglobin saturation <90 %); [33] and Periodic
Limb Movement Index (PLMI, number of PLMS/h of
sleep). Moderate to severe SDB was defined as having
AHI ≥15. The presence of PLMS was defined as having
a PLMI ≥5.
Sleep quality
Participants also completed the Pittsburgh Sleep Quality
Index (PSQI), which is a self-rated questionnaire for
evaluating subjective SQ. The PSQI includes 18 ques-
tions regarding the subjects’ habitual sleep over the past
1 month that are combined into seven clinically derived
component scores, each weighted equally from 0 to 3.
The seven component scores are added to obtain a
global score ranging from 0 to 21. The PSQI has good
internal consistency, test-retest reliability, discriminant
validity, and responsiveness to treatments and has been
used in the ESRD population [34]. PSQI scores >5 reflect
poor SQ.
Depression
The Patient Health Questionnaire-9 (PHQ-9) is a self-
administered, established questionnaire that covers
symptoms of major depressive disorder, as well as their
subsyndromal variants. The PHQ-9 consists of nine
criteria for depression from the Diagnostic and Statis-
tical Manual of Mental Disorders, fourth edition (DSM-
IV). PHQ-9 severity is calculated by assigning scores of
0, 1, 2, and 3 to the response categories of: not at all,
several days, more than half the days, and nearly every
day, respectively, for each of the nine items. PHQ-9 total
score for the nine items ranges from 0 to 27. Scores of
5, 10, 15, and 20 represent cut points for mild, moderate,
moderately severe, and severe depression, respectively.
The PHQ-9 is comparable or superior in operating
characteristics and valid as both a diagnostic and severity
measure [35]. Sensitivity to change has also been con-
firmed [36]. The PHQ-9 was completed by all consent-
ing individuals, and any findings of a positive score for
depression and/or suicidal ideation were reported
promptly to the participant’s primary physician.
Statistical analysis
The study population characteristics and the various
sleep parameters are presented as medians and inter-
quartile ranges (25th and 75th percentiles) for conti-
nuous variables or as frequencies and percentages for
categorical variables. Non-parametric Kruskal-Wallis
tests were used to examine the initial statistical signifi-
cance of the differences among the study groups. For
patient characteristics and sleep parameters that were
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significantly different by the global Kruskal-Wallis test,
Mann-Whitney U tests were performed for pairwise
comparisons of study groups. In order to examine
among-group differences after accounting for demo-
graphic and clinical differences among the study groups,
we performed analyses that compared the study groups
while adjusting for differences in patient characteristics
using analysis of covariance approaches. For each of the
variables of interest, we identified a transformation, typ-
ically square root or logarithmic, that provided a data
scale that better met modeling assumptions. We per-
formed analysis of covariance for each of these trans-
formed variables and tested for differences among study
groups after adjusting for age, sex, race, and body mass
index (BMI) in our primary adjusted analyses. We ob-
tained least squares means for each of the three groups,
and differences between them, and back-transformed the
resulting estimates in order to report estimated differ-
ences on the original data scale. We repeated the
analyses of covariance after including other patient char-
acteristics, such as education level, employment status,
and blood pressure. As the results from these analyses
with expanded adjustments were very similar to our
primary adjusted analyses, we do not report them here.
All analyses were performed with SAS statistical software,
version 9.4 (SAS, Inc., Cary, NC).
Results
Study population
The characteristics for all study participants are shown
in Table 1. Patients in the APD group were the youngest.
Compared with the CKD and the HD groups, the APD
group had higher proportions of women and African-
Americans, with high school education. Notably, most of
the HD patients were unemployed. Overall comparisons
among the groups resulted in significant differences also
for glucose levels (p < 0.001), SBP (p = 0.03) and DBP (p =
0.03), and the number of antihypertensive medications (p
= 0.002). For these variables, HD had significantly higher
glucose levels than APD and CKD. APD patients had sig-
nificantly less SBP than CKD patients and significantly
higher DBP than HD patients, while APD patients took
significantly fewer antihypertensive medications than
CKD and HD patients. Although comparisons did not
reach statistical significance, the APD group partici-
pants tended to be less obese and with a lower waist
circumference compared to CKD and HD patients.
APD patients had significantly (p = 0.003) smaller neck
circumference compared to HD patients.
The APD patients had been on cycler-assisted PD for
a median of 10 (6, 16) months, while the HD patients
had been on thrice weekly in-center HD for a median of
21.5 (9, 49.8) months. All dialysis patients received
adequate dialysis dose. For the HD patients, the median
single-pool Kt/V was 1.6 (1.5, 1.8) and the median urea
reduction ratio (URR) was 73 (69.5, 76). For the APD
patients, the median total weekly Kt/V was 2.34 (1.72,
3.15). The CKD sample had a median eGFR of 17.9
(13.1, 23.3) ml/min/1.73 m2, and a median serum
creatinine of 4.0 (3.1, 4.9) mg/dl. The cause of CKD/
ESRD is also presented in Table 1. The most common
cause of renal dysfunction was diabetic nephropathy
(CKD and HD) and glomerulonephritis (APD).
Subjective and objective sleep characteristics
Continuous parameters of sleep, SDB, PLMS, SQ, de-
pression, and their unadjusted differences across study
groups are shown in Table 2. Compared with the HD
group, the CKD patients had significantly greater TST
and SE. The APD group had significantly greater stages
3 to 4 sleep compared to the CKD patients. Notably,
median AHI was significantly higher in the HD group
compared with the other two groups, but did not differ
between the CKD and the APD patients. APD patients
revealed the least percentage of TST with nocturnal
hypoxemia. Finally, both HD and APD patients reported
significantly poor SQ (high total PSQI score) compared
to the CKD patients. There were no significant differ-
ences in stage 1, stage 2, REM sleep, micro-arousal
index, and PLMI across all three study groups.
Depression results
Results from the PHQ-9 questionnaire and their
unadjusted differences across study groups are also
shown in Table 2. APD patients reported the highest
total PHQ-9 score (moderately severe depression).
However, the among-group comparison was not
statistically significant.
Multivariable results
After adjusting for age, sex, race, and BMI, significant differ-
ences among groups were apparent for TST (p = 0.003),
stages 3 to 4 sleep (p = 0.018), percentage of TST with
nocturnal hypoxemia (p = 0.009), and PSQI scores (p =
0.005) as shown in Table 3. Further adjustment for add-
itional covariates resulted in minimal changes from
the simpler adjustments and are therefore not shown.
Differences among groups after adjustment are illus-
trated in Fig. 1, which shows estimates of least
squares means and 95 % confidence intervals for the
estimates. CKD patients had significantly more TST
than HD patients. They also spent a significantly
lower proportion of TST in stages 3 to 4 sleep and
experienced less percent of TST with nocturnal hyp-
oxemia than HD patients. Both APD and HD patients
had higher average PSQI scores than CKD patients.
No other comparisons of sleep parameters among
groups reached statistical significance.
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Discussion
To our knowledge, this is the first study to examine
objectively and subjectively measured sleep distur-
bances and self-reported presence of symptoms of
depression across APD patients and to compare them
to CKD and HD patients. In our study, sleep efficiency
and sleep architecture were relatively preserved des-
pite being on APD treatment. Sleep parameters of
SDB were not significantly different among study
groups after accounting for differences in age, gender,
race, and BMI. Furthermore, PLMS were not significantly
elevated among the study groups, while self-reported SQ
was poor among dialysis patients, especially those on
HD. Finally, depression was equally present among all
study groups.
PSG is the gold standard for diagnosing SDB and
PLMS in APD patients. According to our multivariate
analyses findings, median AHI, moderate to severe SDB,
and nocturnal hypoxemia were higher but not signifi-
cantly different in the APD and the HD groups com-
pared with the advanced CKD group. These objective
measures of SDB are consistent with previous work
comparing sleep parameters between chronic HD and
CAPD patients by subjective means. According to this
study, no differences were seen between HD and PD
patients in characteristics of sleep problems [37]. It
should be noted that the rate of moderate to severe
sleep apnea in our study cohort is lower, and this is
likely due to the APD patients being younger and
thinner and having a higher proportion of women than
in previous work.
Volume overload comprises a major problem for the
PD patients, especially those with minimal or no
residual renal function. In addition, dry weight in PD
is difficult to achieve. An edema-free state is typically
utilized as the target of volume control. However, PD
patients can be free of edema despite significant vol-
ume overload [38]. No objective measurements (chest
ultrasound, bioelectrical impedance analysis, or neck
and chest MRI) of volume status were included in the
initial study design. The only available information
from the APD patients that could be related to a gross
but not absolutely reliable estimate of their volume
status are neck and waist circumference, the fact that
most had residual renal function and were free of
external anasarca or pedal edema.
Table 1 Characteristics of study population
APD (N = 22) CKD 3b-5 (N = 89) HD (N = 75) p value
Age (years) 37.5 (31.5, 58.3) 51 (42.5, 64.0) 57.5 (46.0, 67.2) 0.001HD > CKDcCKD > APDbHD > APDa
Women 16 (72.7 %) 29 (32.6 %) 25 (33.8 %) 0.002CKD > APDbHD > APDb
Whites 11 (50 %) 70 (78.7 %) 45 (60.8 %) 0.006CKD > HDbCKD > APDb
High school education 21 (95.5 %) 82 (92.1 %) 63 (85.1 %) <0.001
Employed 9 (40.9 %) 40 (44.9 %) 11 (14.9 %) <0.001CKD > HDaAPD > HDb
Smoking 0.12
Current 5 (22.7 %) 13 (14.6 %) 8 (10.8 %)
Former 11 (50 %) 28 (31.5 %) 33 (44.6 %)
Never 6 (27.3 %) 48 (53.9 %) 33 (44.6 %)
BMI (kg/m2) 23.8 (22.6, 28.9) 27.6 (25.0, 31.2) 27.2 (23.5, 31.2) 0.14
Waist circumference (cm) 93 (86.1, 112.9) 102 (90.75, 111.5) 105 (94.0, 115.8) 0.3
Neck circumference (cm) 36.5 (33, 39.4) 38 (36.0, 41.5) 40 (37.2, 43.7) 0.003HD > APDb
Systolic blood
pressure (mmHg)
132 (123, 148) 148.3 (132.0, 165.5) 145.7 (126.6, 169.4) 0.03CKD > APDb
Diastolic blood
pressure (mmHg)
90.8 (72.3, 96.5) 83.8 (73.4, 90.1) 78.5 (70.0, 88.9) 0.03CKD > HDcAPD > HDb
Glucose (mg/dL) 95.3 (86.5, 114.4) 93.7 (985.0, 121) 119 (96.5, 147.2) <0.001HD > CKDaHD > APDb
Total number of
antihypertensives
1 (1, 2.5) 3 (2, 4) 2 (1, 3) 0.002CKD > HDbCKD > APDc
Diabetic nephropathy 3 (13.6 %) 29 (32.6 %) 24 (32 %)
Hypertension 5 (22.7 %) 15 (16.9 %) 14 (18.7 %)
Glomerulonephritis 8 (36.4 %) 16 (18 %) 11 (14.7 %)
Other or unknown causes 6 (27.3 %) 29 (32.5 %) 26 (34.6 %)
Results are presented as medians and interquartile ranges or as percentages. Numbers in parentheses reflect the 25th and the 75th percentile of the variables.
Kruskal-Wallis test was used for the comparison of the distributions along all three study groups. Mann-Whitney U test was performed for all pairwise comparisons
ap < 0.001; bp < 0.01; cp < 0.05 for the pairwise comparisons
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In our multivariate analyses, APD patients had more
PLMS but not significantly different compared to all other
patients. However, it is thought that PLMS may affect up
to 50–70 % of patients with ESRD [12] and this data
measuring PLMI provides essential information for physi-
cians demonstrating that PLMS are also found among
patients undergoing APD. In a study by Jung et al. [14],
PLMI was associated with both a poor cardiovascular
outcome and mortality in maintenance HD patients,
while in a study by Lindner et al. [9], PLMS were asso-
ciated with stroke and cardiovascular risk factors in
patients with ESRD.
In both univariate and multivariate analyses, we found
that patients on HD and on APD had poorer sleep than
patients with CKD. Although patients with HD had
slightly poorer sleep than patients with APD, we were
unable to conclude that there were significant differences
between these two groups after multivariate adjustment.
Table 3 Differences in objective, subjective sleep parameters, and depression between each dialysis group and the CKD group, after
adjustment for age, gender, race, and BMI; 95 % confidence intervals are also shown
APD-CKD 3b–5 HD-CKD 3b–5 p value
Total sleep time (minutes) −26.8 (−80.9 to 27.2) −61.6 (−96.3 to −27.0) 0.003
Sleep efficiency (%) −4.05 (−11.67 to 3.57) −4.36 (−9.26 to 0.54) 0.18
Stage 1 (% of TST) 0.66 (−2.99 to 4.31) 1.17 (−1.23 to 3.58) 0.63
Stage 2 (% of TST) −4.82 (−11.60 to 1.96) −5.02 (−9.36 to −0.68) 0.057
Stages 3 and 4 (% of TST) 2.34 (−0.69 to 5.38) 2.81 (0.80 to 4.81) 0.018
Rapid eye movement sleep (% of TST) 0.41 (−4.83 to 5.65) −1.36 (−4.63 to 1.92) 0.66
Apnea hypopnea index 0.92 (−4.92 to 6.77) 4.84 (0.47 to 9.21) 0.091
Obstructive apnea index 1.25 (−3.51 to 6.02) 2.88 (−0.40 to 6.15) 0.22
Nocturnal hypoxemia (≥3 % of TST) 1.54 (−0.24 to 3.32) 1.82 (0.63 to 3.00) 0.009
Micro-arousal index 1.19 (−2.90 to 5.29) 0.29 (−1.96 to 2.54) 0.84
Periodic limb movement index 2.04 (0.25 to 3.82) 0.46 (−0.50 to 1.41) 0.078
Pittsburgh Sleep Quality Index score 2.54 (0.37 to 4.71) 2.22 (0.74 to 3.71) 0.005
PHQ-9 score 1.51 (−0.48 to 3.50) −0.13 (−1.30 to 1.03) 0.26
Results are presented as differences in least squares means between the identified groups. Numbers in parentheses reflect the endpoints of the 95 % confidence
interval for the indicated group difference
Table 2 Objective, subjective sleep parameters, and depression among study groups
APD (N = 22) CKD 3b–5 (N = 89) HD (N = 75) p value
Total sleep time (minutes) 342.7 (271.7, 475.3) 366.3 (298.3, 433.2) 313.3 (216.2, 388.2) 0.002CKD > HDa
Sleep efficiency (%) 78.3 (57.6, 87.1) 77.8 (67.3, 85.1) 69.8 (59.5, 78.9) 0.018CKD > HDb
Stage 1 (% of TST) 7.2 (4.7, 12.4) 10.1 (6.2, 15.9) 11.6 (6.8, 18.1) 0.11
Stage 2 (% of TST) 56.3 (48, 65.9) 61.2 (53.9, 69.8) 57.5 (51.0, 67.0) 0.13
Stages 3 and 4 (% of TST) 14.0 (4.3, 23.4) 5.4 (1.3, 10.9) 7.3 (1.3, 18.5) 0.009APD > CKDb
Rapid eye movement sleep (% of TST) 20.9 (15.8, 25.6) 20.3 (14.5, 26) 17.9 (11.2, 22.3) 0.11
Apnea-hypopnea index 6.0 (2.3, 22.2) 8.8 (3.2, 27.6) 18.2 (6.7, 30.2) 0.008HD > CKDcHD > APDc
Obstructive apnea index 4.9 (1.8, 18.2) 6.2 (2.0, 17.3) 11.3 (4.1, 23) 0.034HD > CKDbHD > APDb
Nocturnal hypoxemia (≥3 % of TST) 1.1 (0.5, 6,7) 3.8 (1,5, 10) 1.5 (0.9, 8,5) 0.01CKD > APDbCKD > HDb
Micro-arousal index 9.2 (4.7, 13.4) 8.8 (3.9, 15.5) 8.5 (5.4, 14.0) 0.98
Periodic limb movement index 5.7 (1.6, 10.7) 2.4 (0.9, 5.3) 2.7 (0.7, 6.2) 0.14APD > CKDc
Pittsburgh Sleep Quality Index score 8 (6.5, 13) 6 (4, 9) 8 (5, 11) 0.007APD > CKDbHD > CKDc
Patient Health Questionnaire-9 score 11 (8, 14.75) 10 (7, 13) 8 (6.25, 12) 0.08
Results are presented as medians and interquartile ranges or as percentages. Numbers in parentheses reflect the 25th and the 75th percentile of the variables.
Stages 1, 2, 3, and 4, and rapid eye movement sleep are expressed as percent of total sleep time. Apnea hypopnea Index, obstructive apnea index, micro-arousal
index, and periodic limb movement index are expressed as events per hour of total sleep time
Sleep efficiency percentage of total sleep time as a proportion of the total study duration, Apnea hypopnea index, number of apneas/hypopneas during total sleep
time, Obstructive apnea index number of obstructive apneas per hour of total sleep time, Nocturnal hypoxemia ≥3 % total sleep time, percentage of subjects who
had at least 3 % of total sleep time with oxyhemoglobin saturation less than 90 %, Micro-arousal index number of microarousals/hour of sleep, Periodic limb
movement index number of periodic limb movements per hour of total sleep time
ap < 0.001; bp < 0.01; cp < 0.05 for the pairwise comparisons
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Being on HD has been associated with poor SQ [27], and
in our study, HD patients had slightly worse self-reported
SQ compared to the APD patients. The clinical import-
ance and urgency of this difference in subjective SQ is
evidenced by a high prevalence of sleep-promoting medi-
cation use among dialysis patients [39]. In addition, poor
SQ has been associated with an increased prevalence of
cardiovascular disease. Although the causes are multifac-
torial and incompletely understood, the detection and
treatment of SQ in dialysis patients may have a significant
impact on clinical outcomes, since self-reported sleep prob-
lems have strongly been linked to disability days, health
care utilization, and QOL [40] as well as the ability to func-
tion [41]. Finally, addressing SQ in APD patients may be
particularly important since poor SQ may cause some
patients to switch dialysis modality.
Depression is the most common psychological problem
presented by dialysis patients, and in our study, moderate
depression was equally present in all study groups. Our
findings are in accordance to a study by Losso et al. [42]
where depression was compared between HD, APD, and
CAPD patients. They found no differences in depression
among the modalities. The psychological evaluation of the
patient receiving a home-performed dialysis therapy
such as APD is extremely important for two reasons.
First, there is a significant association between depression
scores on standardized questionnaires and patients out-
comes, such as hospitalizations and mortality [43, 44].
Second, a prompt and effective therapy will maximize a
patient’s health-related quality of life (HRQOL) and well-
being [45]. Disturbed sleep, depressed mood, and dimin-
ished HRQOL can also be a potential consequence of
persistent pain among dialysis patients [46, 47].
The results of our study should be interpreted after
taking into account certain limitations. First, the APD
group was demographically and clinically distinct from
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Fig. 1 Multivariate analyses results. Least squares means and 95 % confidence intervals for sleep parameters with significant differences among
groups after adjustment for age, gender, race, and BMI. a Estimates of total sleep time. b Estimates of the percentage of TST in stages 3 and 4 of sleep.
c Estimates of the percentage of TST with oxygen saturation less than 90 % (nocturnal hypoxemia). d Estimates of sleep quality (total score of PSQI)
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the other study groups. Therefore, it is difficult to
uniquely ascribe the observed differences in sleep pa-
rameters among the study groups to group membership
itself because of the presence of differences which may
confound the results. However, the literature describing
sleep disorders tends to underrepresent the APD group.
Second, this was a single-center study and this may limit
the generalizability of our conclusions as well. However,
the patients were receiving standard of care and this
report provides important information to providers and
describes sleep among women on APD. Third, the
sample size was relatively small and provided limited
statistical power to detect significant differences between
groups. With 22 APD patients, we had 80 % power to
detect differences of just over 2/3 of a standard deviation
in magnitude between APD patients and each of the two
other study groups. These moderate-to-large detectable
differences limited our ability to rule out the presence of
smaller differences among groups. The limited power to
protect against false negative findings must also be
weighed against the possibility of false positive findings,
as we have performed a large number of statistical tests
and this can lead to spurious significant findings due to
multiple testing. Finally, no objective measures of vol-
ume overload were included in the initial study design.
Despite these limitations, this study contributes to the
development of meaningful understanding of the rela-
tionship between treatment of kidney failure, SDB, SQ,
and depression, particularly given the limited amount of
sleep data available from APD patients.
Given the complexity of causes of fatigue and poor
sleep in this population, PSG is needed to determine the
full range of potential sleep disorders that may disrupt
sleep and impair daytime function. Given also the nature
of dialysis treatment, it is not possible to use a cross-
over design where patients serve as their own controls.
This obstacle was addressed by comparing the APD
patients with two different groups of patients, one under
a different dialysis modality and one with advanced
kidney dysfunction not yet on dialysis. Despite the popu-
lation disparity, the results presented herein could partly
explain the significance of age and BMI to characterize
the presence of SDB and is in accordance to previous
studies [48–51]. Finally, most studies in the past examining
sleep in larger PD cohorts used subjective measures
(questionnaires, sleep diaries) and PSG has been performed
only in small cohorts of APD patients. This is the main
strength of our work.
Conclusions
In conclusion, this study indicates that APD patients
may have similar sleep parameters and sleep architecture
compared to the other groups despite undergoing ex-
changes overnight. Older age and higher BMI were the
main determinants of moderate to severe SDB and
nocturnal hypoxemia among study groups, providing
important risk factors for physicians to consider when
referring patients for sleep evaluation. Since the PD
population is growing fast, future work should examine
the impact of treating SDB, poor SQ and depression on
functioning, cardiovascular health, and mortality in this
high risk population.
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